🧫 Experiment Protocol
ValidationAlzheimer's diseaseTET2young APPswe/PSEN1 double-transgenic miceproposed
This in vivo experiment investigated the functional role of Tet2 in cognition and amyloid pathology using adeno-associated virus (AAV)-mediated gene delivery in 2×Tg-AD mice. Recombinant AAV vectors were stereotaxically microinjected into the bilateral dentate gyrus regions of the hippocampus to achieve either Tet2 knockdown or overexpression. The study examined young 2×Tg-AD mice to determine how manipulating Tet2 levels affected cognitive function and amyloid load. The researchers found that knocking down Tet2 in young 2×Tg-AD mice resulted in cognitive impairments, while the effects of Tet2 overexpression on cognition and amyloid pathology were also evaluated.
PRIMARY OUTCOME
cognitive performance and amyloid burden
EXPECTED OUTCOMES
1. The intervention targeting TET2 shifts cognitive performance and amyloid burden in the predicted direction relative to the matched control arm.
2. Secondary disease-relevant readouts in Alzheimer's disease remain directionally concordant with the primary endpoint rather than showing isolated single-assay effects.
3. The effect persists after adjustment for baseline covariates, batch effects, or repeated-measures structure used in the study design.
SUCCESS CRITERIA
- Prespecified primary endpoint (cognitive performance and amyloid burden) improves versus control with p < 0.05 or an equivalent corrected threshold used by the study.
- The effect size is biologically meaningful and reproduced across technical/biological replicates or the validation subset.
- Safety, data quality, and missingness remain within protocol-defined bounds so the result is interpretable rather than driven by attrition or assay failure.
PROTOCOL
1. Establish young APPswe/PSEN1 double-transgenic mice cohorts for Alzheimer's disease and predefine inclusion, exclusion, and quality-control criteria before intervention. 2. Apply the experimental manipulation described for TET2, alongside matched control or comparator arms, and document dose, exposure window, and sample timing in a locked protocol log. 3. Measure cognitive performance and amyloid burden together with orthogonal secondary readouts such as molecular, imaging, behavioral, or safety endpoints that are appropriate to the title and study design. 4. Use blinded outcome assessment where feasible, prespecified statistical analysis, and replicate the core readout across biological replicates or an independent validation subset. 5. Interpret results against the baseline study rationale: This in vivo experiment investigated the functional role of Tet2 in cognition and amyloid pathology using adeno-associated virus (AAV)-mediated gene delivery in 2×Tg-AD mice. Recombinant AAV vectors were stereotaxically microinjected into the bilateral dentate